Bharat Biotech
-
Bharat Biotech says it followed ‘step-by-step’ approach for contract, approval of Covaxin in Brazil
Scroll Staff
-
Coronavirus: Brazil to suspend Covaxin contract amid inquiry into deal
Scroll Staff
-
Brazil launches investigation into contract to buy Bharat Biotech’s Covaxin
Scroll Staff
-
Covaxin shows 77.8% efficacy in phase 3 trials, say reports
Scroll Staff
-
Bharat Biotech submits phase 3 trial data of Covaxin, expert panel to meet today to discuss results
Scroll Staff
-
Covaxin does not contain newborn calf serum, clarifies health ministry amid speculation
Scroll Staff
-
Supplying Covaxin to Centre at Rs 150 per dose is not sustainable in long run, says Bharat Biotech
Scroll Staff
-
Top 10 coronavirus updates: AIIMS Delhi to start Covaxin trial for children aged 6-12 from Tuesday
Scroll Staff
-
Covaxin’s phase three trial data likely to be published in a week, says Centre
Scroll Staff
-
Coronavirus: US drug regulator rejects emergency use approval for Bharat Biotech’s Covaxin
Scroll Staff
-
Covid: Tamil Nadu extends lockdown, but allows liquor shops, salons to open in 27 districts
Scroll Staff
-
Covaxin trial data to be released in July, says Bharat Biotech as it criticises study on antibodies
Scroll Staff
-
Even if WTO waives IP on vaccines, India will face challenge translating this into mass production
Yogesh Pai Prashant Reddy T
-
Top 10 coronavirus updates: Moderna says its vaccine is effective in adolescents aged 12 to 17
Scroll Staff
-
WHO says ‘more information required’ for Covaxin approval as Bharat Biotech submits 90% documents
Scroll Staff
-
Covid-19: Covaxin effective against variants first found in India and UK, says Bharat Biotech
Scroll Staff
-
Coronavirus: Russia’s Sputnik V vaccine to be available in India from next week, says Centre
Scroll Staff
-
Coronavirus: Bharat Biotech gets approval for clinical trials of Covaxin on children aged 2-18
Scroll Staff
-
Coronavirus: No Covaxin shot for 18 to 44 age group in Delhi from Thursday
Scroll Staff
-
As Indian government offers some answers on Covaxin patent rights, more questions emerge
R Ramakumar